Shares of Zydus Lifesciences Ltd are trading flat after touching a day’s high of Rs 1,002.85 on 14th August. This came after the company said the US Food and Drug Administration (USFDA) had concluded a surveillance inspection at its formulation manufacturing plant in Baddi, Himachal Pradesh, and also announced the closure of an FDA inspection at its SEZ II formulation plant in Ahmedabad.

At its Ahmedabad, Gujarat plant, the USFDA conducted a pre-approval inspection (PAI) for three products and reviewed general cGMP from 11th to 13th August, 2025, concluding with no observations, indicating full compliance.

While at its Baddi, Himachal Pradesh plant, an inspection from 4th to 13th August, 2025, ended with four observations, none related to data integrity, and the company said it will work closely with the USFDA to address them promptly.

Zydus Lifesciences posted a 3.3% rise in net profit to Rs 1,467 crore in Q1, supported by a forex gain of Rs 57 crore compared to a forex loss of Rs 25 crore in the same period last year. Revenue grew 6% year-over-year to Rs 6,574 crore.

EBITDA for the quarter was flat at Rs 2,089 crore, while EBITDA margins narrowed to 31.8% from 33.6% a year ago.

US sales were steady compared to last year, rising 2.5% from the March quarter to $372 million.

Managing Director Sharvil Patel stated that the company is on track to meet its FY2026 goals and views innovation as a key driver of sustainable growth.

At 1:04 PM, the shares of Zydus Lifesciences were trading 0.26% lower at Rs 986.05 on NSE.

Tired of missing hot stocks? Unicorn Signals provides powerful tools like stock scans and more help you make informed trading decisions. Download now and take control of your portfolio!